SBIR/STTR Research Award
CORNAUCOPIA - A METHOD TO DELIVER MULTIPLE BNABS IN THE SAME RNA
Award amount
$300,000Program and phase
SBIR · Phase IAward year
2024Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- LYNNTECH INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- PMVAL8J63516
- Solicitation number
- PHS-2024-1
- Topic code
- 124
Research abstract
Development of Next-Generation Devices and Materials-Based Platforms for the Administration of HIV-1 Broadly Neutralizing Antibodies: NIAID and its partners are building on the success of the Antibody Mediated Prevention (AMP) trials by engineering next-generation broadly neutralizing antibody (bNAb) candidates to enhance potency, increase tissue levels, extend half-life, and contend with the ever-evolving global diversity of HIV-1. Developing bNAb cocktails presents additional challenges: complex pharmacokinetics, larger injection volumes, multi-product formulations, and complicated manufacturing. The goal of this program is to support small businesses in the development of devices and/or materials for administration of HIV-1 bNAb(s) and bNAb derivatives (e.g., bispecific antibodies), resulting in increased protection from infection. The goal of this contract is to develop a method to deliver multiple bNAbs in the same RNA.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Compact, Long-lasting Hydrogen Peroxide Generator of Enhanced Stability
- Event-Driven High Angular Rate Star Tracker
- Cost-Effective Reusable Thermal Protection System for Re-Entry Vehicles
- Next-Gen Multi-Spectral Scene Projection Using Quantum Materials
- High-Pressure Electrochemical Lift Pump
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- DEVELOPMENT OF A NEXT-GENERATION IMMUNOPREVENTION PLATFORM AGAINST HIV-1
- HIGH-DOSE AND SUSTAINED DELIVERY OF HIV-1 BROADLY NEUTRALIZING ANTIBODIES VIA SUBCUTANEOUS INJECTION OF HYDROGEL-BASED MICROPARTICLE FORMATIONS
- VECTOR-BASED DELIVERY OF HIV BROADLY NEUTRALIZING ANTIBODIES
Research funding history
1,079 SBIR/STTR records share this UEI (1988–2025). Reported award amounts total $327,411,388. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Defense, Department of Health and Human Services, National Aeronautics and Space Administration, Department of Energy, National Science Foundation, Environmental Protection Agency